Third-generation EGFR-TKIs such as abivertinib, rociletinib, nazartinib, and olmutinib, which target the EGFR T790M mutation, can be used to overcome resistance caused by first- and second-generation EGFR-TKIs used as first-line treatment for NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.